|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||16.49 - 16.53|
|52-week range||16.49 - 16.53|
|Beta (5Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
PARIS, January 31, 2023--Regulatory News: EUROAPI (Paris:EAPI) progressively restarted prostaglandin production at its Budapest site on January 19.
PARIS, January 11, 2023--Regulatory News: The Board of Directors of EUROAPI (Paris:EAPI) proposes the ratification of the appointment by co-optation of a new independent director, Mattias Perjos, as of January 11, 2023. Corinne Le Goff, after serving as an independent member on the Board of Directors since May 6, 2022, has resigned from her directorship as of January 11, 2023. Corinne Le Goff has been appointed as President and Chief Executive Officer of Imunon.
PARIS, January 09, 2023--Regulatory News: EUROAPI (Paris:EAPI) announces that its Board of Directors has approved a €40 million investment for the implementation of a new production technology dedicated to vitamin B12 at its site in Saint-Aubin-lès-Elbeuf (Seine-Maritime, France). The project should enable EUROAPI to increase its manufacturing capacity by 2025 while reducing its environmental footprint. This investment benefits from a total financial support of €7.9 million, from the French Gove